Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 14Terminated 4Withdrawn 1Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Sarcoma 2Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 86Bevacizumab 66Capecitabine 65Fluorouracil 48tislelizumab 41Gemcitabine 40Drug Therapy 39Leucovorin 38sintilimab 35Irinotecan 34lenvatinib 27Cisplatin 27HMPL-013 25S 1 (combination) 23camrelizumab 22Immune Checkpoint Inhibitors 21irinotecan sucrosofate 20apatinib 20Surgical Procedures, Operative 20Radiotherapy 20Injections 20130-nm albumin-bound paclitaxel 20toripalimab 19Paclitaxel 18Folfox protocol 17pembrolizumab 15Immunotherapy 15Cetuximab 15Specimen Handling 14regorafenib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × AZD 6244 × Gastrointestinal × Clear all
NCT07619521 2026-06-02

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
31 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡